|
Monday April 21, 2008
|
1:20 pm -
2:20 pm
|
- New end-to-end clinical trial strategies: Integrating the planning process for a number of trials and creating modular, reusable tools
- C-Path’s development of US Diagnostic Standards – performance standards and an evaluation process for "companion diagnostics" C-Path’s progress on accelerating development of lifesaving therapies
|
|
|
|
2:25 pm -
3:25 pm
|
- Public-private electronic data collaboration for population-based monitoring of adverse effects
- How the FDA thinks about safety regulation impact on drug development
- Pharma’s evolving role in surveillance and participation in an electronic infrastructure
|
|
|
|
|
Tuesday April 22, 2008
|
9:10 am -
10:10 am
|
- Evaluation of trends in technology assessment and evaluation by government purchasers, payers and employers
- Approaches and tools used by different health systems (domestic and international) to measure the value of access to technology and innovation (e.g. restrictions by access, formulary tiers, etc.)
- How pharmacogenomics impacts pricing and reimbursement
- Strategies to demonstrate value in context of new evidence-based medicine approaches and evaluation committees
|
|
|
|
|
Wednesday April 23, 2008
|
9:15 am -
9:55 am
|
- Substantiating reimbursement for diagnostics and therapeutics based on market principles by demonstrating significantly enhanced outcomes
- Implementing a methodology-focused and implementation-focused research agenda to determine how best to apply evaluation methods to determine reimbursement
- Partnerships with health systems to adopt IT necessary to analyze pharmacogenomic and clinical data to support patient and physician access to new medical technologies and information
|
|
|
|
10:00 am -
10:40 am
|
- Managing the tension between managed care and consumers in choice of providers and cost of care
- Working collaboratively with providers and payers while offering convenience to consumers
- Sharing meaningful information back to payers to manage utilization and to manufacturers on efficacy
|
| Moderator: |
|
|
David Woods, PhD
Editor-in-Chief and Director, US Corporate Relations
Rx Communications, LTD
|
| Panelists: |
|
Stanley B. Blaylock
President and CEO, Medmark, a Walgreens Specialty Pharmacy;
SVP, Walgreens Specialty Pharmacy and Home Care;
Divisional VP, Walgreen Co.
 View Biography
|
|
Edmund Pezalla, M.D., MPH
National Medical Director, Aetna Pharmacy Management
Aetna, Inc.
View Biography
|
|
|
World Congress welcomes our attendees celebrating the Passover holiday and is pleased to provide kosher meals throughout the conference.
|
Printer Friendly
Email A Colleague
Bookmark Page
